Phase II clinical trial results published today in Circulation (2006;114:2374-2381) highlight the potential of a simple, once-daily dosing regimen of the novel, oral anticoagulant rivaroxaban (BAY 59-7939), a direct Factor Xa inhibitor. [click link for full article]
More...